Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2018 1
2019 2
2020 2
2021 2
2022 7
2023 5
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
Bergaggio E, Tai WT, Aroldi A, Mecca C, Landoni E, Nüesch M, Mota I, Metovic J, Molinaro L, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco RB, Li T, Klein D, Irvine DJ, Papotti M, Savoldo B, Dotti G, Chiarle R. Bergaggio E, et al. Among authors: aroldi a. Cancer Cell. 2023 Dec 11;41(12):2100-2116.e10. doi: 10.1016/j.ccell.2023.11.004. Epub 2023 Nov 30. Cancer Cell. 2023. PMID: 38039964 Free PMC article.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro A, Sacco A, Stagno F, Serafini M, Mottadelli F, Cazzaniga G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini C, Elli EM, Mologni L, Piazza R. Crespiatico I, et al. Among authors: aroldi a. Blood. 2024 Apr 4;143(14):1399-1413. doi: 10.1182/blood.2023021349. Blood. 2024. PMID: 38194688 Free article.
Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Gambacorti-Passerini C, et al. Among authors: aroldi a. Am J Hematol. 2016 Jan;91(1):67-75. doi: 10.1002/ajh.24247. Am J Hematol. 2016. PMID: 26588811 Free article. Review.
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.
Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara CM, Placantonakis DG, Bruno B. Boccalatte F, et al. Among authors: aroldi a. Cancers (Basel). 2022 Oct 18;14(20):5108. doi: 10.3390/cancers14205108. Cancers (Basel). 2022. PMID: 36291891 Free PMC article. Review.
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making.
Civettini I, Zappaterra A, Granelli BM, Rindone G, Aroldi A, Bonfanti S, Colombo F, Fedele M, Grillo G, Parma M, Perfetti P, Terruzzi E, Gambacorti-Passerini C, Ramazzotti D, Cavalca F. Civettini I, et al. Among authors: aroldi a. Br J Haematol. 2024 Apr;204(4):1523-1528. doi: 10.1111/bjh.19200. Epub 2023 Dec 9. Br J Haematol. 2024. PMID: 38070128 Free article.
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A, Mauri M, Ramazzotti D, Villa M, Malighetti F, Crippa V, Cocito F, Borella C, Bossi E, Steidl C, Scollo C, Voena C, Chiarle R, Mologni L, Piazza R, Gambacorti-Passerini C. Aroldi A, et al. J Cell Mol Med. 2023 Oct;27(20):3053-3064. doi: 10.1111/jcmm.17868. Epub 2023 Aug 31. J Cell Mol Med. 2023. PMID: 37654003 Free PMC article.
27 results